Generic and biosimilar drugs group Sandoz has agreed to pay $450 million to settle litigation with 43 US states and other plaintiffs claiming that it carried out anti-competitive activities, including price-fixing. Sandoz was formerly part of Novartis before spinning out as an independent company in October 2023, and its former parent previously settled two other antitrust lawsuits alleging price-fixing. It also paid $185 million to resolve the civil portion of that complaint. After it separated, in 2024, Sandoz paid a $265 million settlement to resolve similar accusations in Pennsylvania, once again without admitting any wrongdoing. The only remaining claims are those brought by individual plaintiffs who opted out of class settlements, and Sandoz said it "continues to defend itself vigorously" in those lawsuits.